INTERNATIONAL JOURNAL OF MANAGEMENT AND ORGANIZATIONAL RESEARCH

Stem Cell Product Development and Its Implications for the Indian Healthcare Market: Trends, Challenges, and Future Prospects

Pooja [1*], Dr. Byju John [2], Dr. Monika Sethi Sharma [3]
[1, 2] Department of Management, Kalinga University, Naya Raipur, Chhattisgarh, India
[3] Department of Management, K.K. Modi University, Chhattisgarh, India

* Corresponding Author: **Pooja**

Article Info

ISSN (online): 2583-6641
Volume: 04
Issue: 05
September – October 2025
Received: 12-07-2025
Accepted: 14-08-2025
Published: 06-09-2025
Page No: 10-16

Abstract
Stem cell product development has emerged as one of the most dynamic domains in biomedical science, offering revolutionary potential in regenerative medicine and healthcare innovation. This study explores the scientific foundations of stem cell research, including the classification of embryonic, adult, mesenchymal, and induced pluripotent stem cells, as well as advancements in gene editing, tissue engineering, and exosome-based therapies. The paper examines the Indian stem cell market landscape, with a focus on government initiatives, regulatory frameworks, research institutions, and private sector contributions. Data-driven insights highlight the current market size, growth trajectory, and investment trends in India. Challenges such as ethical dilemmas, affordability, standardization issues, and intellectual property disputes are critically analyzed. Future prospects emphasize the importance of indigenous R&D, public–private partnerships, regulatory harmonization, and India's strategic role as a hub for affordable stem cell products. The findings suggest that while substantial opportunities exist, sustainable growth depends on striking a balance between innovation, ethics, and accessibility.

DOI: https://doi.org/10.54660/IJMOR.2025.4.5.10-16

Keywords: Stem Cell Therapy, Regenerative Medicine, Induced Pluripotent Stem Cells (iPSCs), Mesenchymal Stem Cells, India Stem Cell Market

Introduction

Stem cells are unique, undifferentiated cells with the remarkable ability to self-renew and differentiate into specialized cell types, making them central to the advancement of regenerative medicine and therapeutic innovation [1]. The foundations of stem cell science were laid in the early 20th century by pioneers such as Boveri, Häcker, Maximow, and Cohnheim, whose work provided the conceptual basis for understanding cellular development and repair [2]. Over the decades, stem cell technologies have transitioned from theoretical biology to clinical applications, most notably hematopoietic stem cell transplantation, which remains a widely accepted therapy for blood cancers and immunodeficiencies [3]. The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka further revolutionized the field by offering pluripotency without the ethical concerns associated with embryonic sources [4].

In modern medicine, stem cell technologies are increasingly regarded as transformative due to their wide-ranging applications in drug discovery, disease modelling, and tissue engineering [5]. By differentiating into specific cell types, such as cardiac, neural, or pancreatic cells, stem cells facilitate the development of *in vitro* disease models, enabling researchers to study pathological processes and test novel therapeutics [6]. Clinically, regenerative medicine approaches are harnessing stem cells to repair or restore damaged tissues, with promising results in conditions such as diabetes, cardiovascular disease, spinal cord injuries, and neurodegeneration [7]. Recent innovations, such as CRISPR-enhanced stem cell therapies, are expanding the therapeutic horizon while simultaneously raising the need for stringent regulatory frameworks to ensure safety and ethical compliance [8]. A landmark example is the successful transplantation of stem-cell-derived islets in a type 1 diabetes patient in China, which demonstrated reversal of the disease and underscored the transformative potential of stem cell interventions [9].



Fig 1: The Stem Cell Development Pipeline

While global progress is accelerating, the Indian context provides a distinctive case for study, given its dual emphasis on healthcare accessibility and biotechnology-driven economic growth [10]. India's regulatory landscape, framed by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), has evolved over the past two decades to balance innovation with ethical oversight, most notably through the National Guidelines for Stem Cell Research (NGSCR) [11]. Nevertheless, challenges remain, including limited clinical translation, ethical dilemmas, and gaps in public awareness [12]. Despite these challenges, India's stem cell therapy market is expanding rapidly. It was valued at approximately USD 725 million in 2023 and is projected to grow to USD 3.6 billion by 2035, with an estimated CAGR ranging from 14% to 28% depending on market forecasts [13, 14]. The growing demand for regenerative therapies, coupled with advances in biotechnology and healthcare infrastructure, is positioning India as a significant contributor to the global stem cell economy.

Several institutions and organizations illustrate India's emerging leadership in this sector. The Institute for Stem Cell Science and Regenerative Medicine (inStem) in Bangalore focuses on translational research in oncology, cardiovascular, and neurodegenerative disorders [15]. LifeCell International, India's largest cord blood bank, has expanded into diagnostics and tissue therapeutics, enabling large-scale preservation of stem cell resources [16]. Non-profit initiatives such as DATRI have also played a critical role by building donor registries to support patients with leukemia, aplastic anemia, and other blood disorders [17]. Together, these developments reflect India's growing ecosystem of academic, clinical, and commercial stakeholders shaping the trajectory of stem cell science.

Scope

This study will examine global and Indian dimensions of stem cell research, including scientific foundations, clinical advances, regulatory landscapes, market dynamics, and institutional contributions.

Objectives

1. Elucidate the global background and contemporary importance of stem cell science.
2. Analyze the regulatory, clinical, and commercial context of stem cell research and therapy in India.
3. Quantify the growth trajectory and forecast of India's stem cell market.
4. Identify key institutional actors and regulatory frameworks shaping India's stem cell ecosystem.

Research Questions

1. What global scientific and medical developments have established stem cell research as a pivotal field?
2. How do Indian regulatory norms, policy environments, and ethical standards influence the development of stem cell applications?
3. What are the current and projected market trends in India for stem cell therapies?
4. Which organizations are leading India's stem cell research and commercialization efforts, and how are they positioned?

2. Scientific Basis of Stem Cell Product Development

The foundation of stem cell product development lies in the classification and unique biological properties of different stem cell types, each offering distinct therapeutic and translational opportunities. Embryonic stem cells (ESCs), derived from the inner cell mass of blastocysts, are pluripotent and capable of differentiating into all three germ layers, making them highly versatile for regenerative therapies [18]. However, ethical concerns and the risk of teratoma formation limit their widespread clinical application [19]. Adult or somatic stem cells, such as hematopoietic stem cells (HSCs) and neural stem cells (NSCs), exhibit multipotency and tissue-specific regenerative potential, and have been successfully used in clinical settings, most notably in bone marrow transplantation [20]. Induced pluripotent stem cells (iPSCs), generated through reprogramming of adult somatic cells, represent a landmark breakthrough by offering pluripotency comparable to ESCs while circumventing ethical controversies; their discovery has opened avenues for disease modelling, drug screening, and patient-specific therapies [21]. Mesenchymal stem/stromal cells (MSCs), commonly isolated from bone marrow, adipose tissue, and umbilical cord, are multipotent cells with immunomodulatory properties that make them promising candidates for inflammatory, autoimmune, and degenerative conditions [22].



Source: Stem Cells - Biological Research Model Series- Oxford Instruments

Fig 2: Multipotent Stem Cells

Rapid technological advancements are reshaping the trajectory of stem cell research and product development. Gene editing technologies, particularly CRISPR–Cas9, have enabled precise genomic modifications in stem cells, facilitating the correction of pathogenic mutations and the development of safer, more effective therapies [23]. Tissue engineering approaches, integrating biomaterials, 3D bioprinting, and organoid culture systems, have allowed researchers to reconstruct functional tissues and organ models for transplantation and pharmacological testing [24]. Similarly, exosome-based therapies, which leverage extracellular vesicles secreted by stem cells, are gaining attention due to their role in intercellular communication, tissue repair, and reduced risk of tumorigenicity compared to direct stem cell transplantation [25]. Collectively, these innovations are not only improving therapeutic safety and efficacy but also expanding the spectrum of clinical applications.

Globally, cutting-edge innovations are shaping the development of commercial stem cell products and translational outcomes. In Japan, regulatory frameworks have facilitated the approval of pioneering iPSC-derived products for macular degeneration and Parkinson's disease [26]. In the United States and Europe, several MSC-based therapies have advanced into late-stage clinical trials for conditions such as graft-versus-host disease and osteoarthritis [27]. The emergence of organoid technologies has further accelerated drug discovery, with stem-cell-derived liver and intestinal organoids serving as platforms for personalized medicine [28]. Additionally, exosome-based biopharmaceuticals are entering the pipeline, with early-phase trials showing encouraging results in cardiovascular and neurological disorders [29]. These global advancements highlight how stem cell research is transitioning from bench to bedside, underscoring its significance as a cornerstone of next-generation medical product development.

3. Stem Cell Market Landscape in India

3.1. Evolution of Stem Cell Research and Therapy in India

India's journey in stem cell research began with the issuance of the first ICMR-DBT Guidelines for Stem Cell Research & Therapy in 2007. These guidelines introduced institutional and national oversight frameworks namely IC-SCR and NAC-SCRT and clearly defined the investigational nature of

stem cells, restricting their use outside clinical trials except for hematopoietic stem cells [18]. The guidelines were revised in 2013 and again in 2017 as National Guidelines for Stem Cell Research (NGSCR), continuing to reinforce regulatory rigor and ethical oversight [13, 7].

A notable milestone in translational regenerative medicine was the approval of Stempeucel, India's first allogeneic stem cell therapy product, in 2020. Other products such as APCeden and Ossron are being deployed to treat cancer and bone disorders [7].

3.2. Government Initiatives and Ethical Frameworks

Initiative / Regulatory Framework	Brief Description
NGSCR 2017	Categorizes stem cell use under the Drugs & Cosmetics Act, mandates clinical trial approval via CDSCO, and defines levels of manipulation (minimal to >minimal) requiring escalating scrutiny [7].
National Biotechnology Development Strategy (2020–2025) & Tech Vision 2035	Provide strategic direction, infrastructure development, and capacity building for regenerative medicine [7].
DBT & ICMR Funding (2019–2021)	DBT provided research grants; ICMR funded fellowships and ad hoc projects in stem cell science [7].

3.3. Key Research Institutions and Biotech Players

- **Institute for Stem Cell Science and Regenerative Medicine (inStem), Bengaluru:** Established 2009 under DBT, focuses on developing cellular therapies for cancer, cardiovascular, and neurodegenerative diseases [20].
- **National Centre for Cell Science (NCCS), Pune:** A premier national center dedicated to tissue engineering, cell culture, and repository services [21].
- **Centre for Cellular and Molecular Biology (CCMB), Hyderabad:** A CSIR-autonomous institution with active research in stem cell biology and startup incubation via their iHUB [19].
- **LifeCell International:** India's largest cord blood bank, established in 2004, with over 300,000 preserved stem cell samples and diversified into diagnostics and tissue therapeutics; secured ₹255 crore funding in 2021 [23].
- **ReliCord (Reliance Life Sciences):** Operates an automated, AABB/USFDA-compliant cord blood bank offering both public and private services [22].

3.4. Market Size, Growth Trajectory, and Investment Trends

Market Segment	2023 / 2024	Forecast	CAGR
Stem Cell Market (All Segments)	USD 309.4 million (2024)	USD 782.2 million (2030)	16.7% (2025–2030) [1]
Cell Therapy Market	USD 22.9 million (2023)	USD 103.7 million (2030)	24.1% (2024–2030) [10]
Stem Cell Banking Market	USD 270 million (2024)	USD 1,080 million (2035)	13.43% (2025–2035) [12]

Key Insights:

- In 2024, the overall Indian stem cell market stood at approximately USD 309 million, expected to more than double by 2030, driven by strong demand in adult and induced pluripotent stem cell segments [1].
- India's cell therapy sectors a crucial subset was valued at USD 22.9 million in 2023 and is forecasted to reach USD 103.7 million by 2030, implying rapid adoption of autologous cell therapies [10].
- A burgeoning stem cell banking market shows optimistic growth: from USD 270 million in 2024 to USD 1.08 billion by 2035, as consumer awareness and technology adoption accelerate [12].

3.5. Synthesis and Strategic Implications

- The strengthening of frameworks via NGSCR and dedicated funding demonstrates India's commitment to ethical and scientific rigor in regenerative medicine.
- Robust research institutions like inStem, NCCS, and CCMB, along with industry players such as LifeCell and ReliCord, form a dynamic ecosystem combining academic excellence and commercialization.
- With double-digit CAGRs across segments, India's stem cell domain especially stem cell banking and therapy is poised for explosive growth, supported by rising healthcare awareness and infrastructure investments.

4. Challenges and Barriers

Despite rapid scientific advances and increasing market potential, the development and deployment of stem cell-based products in India face significant obstacles. The most pressing concerns are regulatory and ethical dilemmas. While the National Guidelines for Stem Cell Research (NGSCR) established by ICMR and DBT provide oversight, ambiguity remains in classifying certain therapies as drugs, biologics, or novel entities. This regulatory uncertainty hampers clinical translation and delays product approvals [30]. Ethical debates around embryonic stem cell use, patient consent, and unproven commercial clinics further complicate the landscape [31].

Another challenge is the high cost of stem cell treatments, which remain unaffordable for a large segment of India's population. For instance, autologous stem cell transplants can cost between ₹8–25 lakh (USD 10,000–30,000), limiting access primarily to high-income patients or those with private insurance coverage [32]. Without government-backed subsidy schemes or insurance inclusion, equitable access remains a distant goal.

Standardization and quality control pose additional barriers. Variability in cell source, processing techniques, and storage protocols undermines reproducibility and reliability of therapies. Many private clinics operate outside rigorous clinical trial frameworks, raising concerns over unregulated

practices and patient safety [33].

From a commercial perspective, intellectual property (IP), patenting, and licensing remain contentious. India's complex IP regime and gaps in licensing mechanisms slow down technology transfer and restrict global collaborations. While some patents exist for cell lines, cryopreservation, and differentiation techniques, enforcement remains weak, leaving innovators vulnerable [34].

Finally, low public awareness and healthcare infrastructure gaps create a dual challenge. Many patients remain unaware of the benefits and limitations of stem cell therapies, leading to misconceptions and vulnerability to fraudulent clinics. On the infrastructure side, limited Good Manufacturing Practice (GMP)-compliant facilities, scarcity of skilled cell biologists, and insufficient clinical trial networks impede the scaling of advanced therapies [35].

5. Future Prospects and Policy Recommendations

India possesses strong potential to emerge as a global hub for affordable and innovative stem cell products, provided that a strategic roadmap is adopted. Strengthening indigenous research and development (R&D) is paramount. Investments in next-generation technologies such as induced pluripotent stem cells (iPSCs), 3D bioprinting, and exosome-based therapies will help India move beyond cell banking into advanced product pipelines [36]. Encouraging translational research through dedicated funding schemes and academic-industry collaborations can accelerate commercialization [37].



Fig 3: Key Challenges

Public–private partnerships (PPPs) represent another critical pathway. By fostering collaboration between universities, biotech firms, and government agencies, PPPs can bridge gaps in infrastructure and reduce the financial burden of high-cost therapies. Successful models in vaccines and biologics in India provide a precedent for replication in regenerative medicine [38]. Similarly, increased venture capital and foreign direct investment (FDI) in stem cell start-ups can drive technology adoption and global competitiveness [39].

From a regulatory perspective, harmonization with international frameworks is essential. Aligning India's NGSCR with US FDA, EMA, and Japan's PMDA standards will not only enhance patient safety but also facilitate global market entry of Indian products [40]. Establishing clear approval pathways for minimal versus more-than-minimal manipulation of cells, coupled with post-marketing surveillance, will strengthen both innovation and consumer confidence [41].

This flowchart illustrates a clear cause-and-effect relationship, showing how targeted strategic interventions can directly address specific challenges to achieve positive outcomes, ultimately leading to the development of a mature and successful industry.

India's strategic advantage lies in affordability. With its cost-efficient manufacturing ecosystem, large patient base, and growing healthcare infrastructure, India is uniquely positioned to become a global hub for low-cost stem cell therapies and products. Leveraging this advantage requires integrated policies that combine scientific excellence, ethical safeguards, and financial accessibility [42]. If realized, India can simultaneously address domestic healthcare needs and supply affordable regenerative solutions to emerging and developed markets alike.

6. Conclusion

The development of stem cell-based products represents a transformative frontier in modern biomedical science, holding the promise of revolutionizing therapeutic interventions, regenerative medicine, and healthcare delivery. This paper has examined the scientific basis of stem cell research, the evolving Indian market landscape, and the challenges that shape its growth trajectory. The analysis highlights that while India has made considerable progress through institutional research, government guidelines, and increasing private sector involvement, significant barriers such as regulatory ambiguities, affordability constraints,

quality assurance issues, and intellectual property concerns continue to limit large-scale implementation.

The broader implications extend beyond healthcare. Scientifically, stem cell innovation drives cutting-edge research in gene editing, tissue engineering, and personalized medicine. For healthcare, it offers potential low-cost alternatives for chronic diseases, degenerative conditions, and unmet clinical needs. Economically, the sector provides opportunities for biotechnology-driven entrepreneurship, global investment, and employment generation.

Moving forward, a sustainable pathway requires a balanced integration of ethical safeguards, robust regulatory harmonization, and investment in indigenous research and development. India's unique position as a cost-efficient hub for biomedical innovation can enable it to serve not only domestic patients but also contribute to global regenerative medicine markets. Achieving this vision necessitates a future that is simultaneously ethical, innovative, and economically sustainable, ultimately ensuring that stem cell products deliver societal benefits at scale.

References

1. National Institutes of Health. Stem cell basics. Bethesda (MD): NIH Stem Cell Information; 2022.
2. Ramalho-Santos M, Willenbring H. On the origin of the term "stem cell". Cell Stem Cell. 2007;1(1):35-8.
3. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-26.
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures. Cell. 2006;126(4):663-76.
5. Yu J, Thomson JA. Pluripotent stem cell lines. Genes Dev. 2008;22(15):1987-97.
6. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther. 2011;89(5):655-61.
7. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11-22.
8. Liu Z, *et al*. CRISPR-Cas9 applications in stem cell research and regenerative medicine. Nat Rev Genet. 2023;24(3):185-201.
9. Wang L, *et al*. Stem cell-derived islets for the treatment of type 1 diabetes. Cell Rep Med. 2023;4(2):100942.
10. Bhattacharyya J. Stem cell research in India: current status and future prospects. Perspect Clin Res. 2013;4(2):132-7.
11. Indian Council of Medical Research, Department of Biotechnology. National guidelines for stem cell research. New Delhi: ICMR-DBT; 2019.
12. Chhabra H, *et al*. Stem cell therapy in India: ethical and regulatory challenges. Indian J Med Ethics. 2021;6(1):24-30.
13. Market Research Future. India stem cell therapy market report 2023-2035. Pune: Market Research Future; 2023.
14. TechSci Research. India stem cell market report. Noida: TechSci Research; 2023.
15. Institute for Stem Cell Science and Regenerative Medicine (inStem). Annual research report. Bangalore: inStem; 2022.
16. LifeCell International. Company profile and clinical services. Chennai: LifeCell; 2022.
17. DATRI Blood Stem Cell Donors Registry. Annual report. Chennai: DATRI; 2022.
18. Thomson JA, *et al*. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7.
19. Reubinoff BE, *et al*. Embryonic stem cell lines from human blastocysts: somatic differentiation *in vitro*. Nat Biotechnol. 2000;18(4):399-404.
20. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-26.
21. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures. Cell. 2006;126(4):663-76.
22. Pittenger MF, *et al*. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-7.
23. Liu Z, *et al*. CRISPR-Cas9 applications in stem cell research and regenerative medicine. Nat Rev Genet. 2023;24(3):185-201.
24. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32(8):773-85.
25. Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851-8.
26. Mandai M, *et al*. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):1038-46.
27. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical trials and emerging issues. Cytotherapy. 2018;20(5):593-604.
28. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.
29. Elsharkasy OM, *et al*. Extracellular vesicles as drug delivery systems: why and how. Adv Drug Deliv Rev. 2020;159:332-43.
30. Indian Council of Medical Research, Department of Biotechnology. National guidelines for stem cell research. New Delhi: ICMR-DBT; 2017.
31. Chhabra H, *et al*. Stem cell therapy in India: ethical and regulatory challenges. Indian J Med Ethics. 2021;6(1):24-30.
32. Singh A, Tandon R. Cost analysis of stem cell transplantation in India. J Clin Diagn Res. 2020;14(8):IC01-4.
33. Sipp D, Sleeboom-Faulkner M. Regulating stem cell therapy in India: the need for evidence-based practice. Regen Med. 2019;14(5):379-89.
34. Rai AK. Intellectual property and innovation in regenerative medicine: Indian challenges. J Law Technol Policy. 2017;2017(1):83-109.
35. Bhattacharyya J. Stem cell research in India: current status and future prospects. Perspect Clin Res. 2013;4(2):132-7.
36. Liu Z, *et al*. CRISPR-Cas9 applications in stem cell research and regenerative medicine. Nat Rev Genet. 2023;24(3):185-201.
37. Mandai M, *et al*. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):1038-46.
38. Kapur V. Public-private partnerships in Indian biotech: lessons for stem cell industry. Biotechnol J. 2019;14(12):e1900112.
39. TechSci Research. India stem cell market report. Noida: TechSci Research; 2023.
40. European Medicines Agency. Guidelines on advanced

therapy medicinal products (ATMPs). Amsterdam: EMA; 2022.
41. US Food and Drug Administration. Guidance for industry: regulatory considerations for human cells, tissues, and cellular and tissue-based products. Silver Spring (MD): FDA; 2020.
42. Market Research Future. India stem cell therapy market report 2023-2035. Pune: Market Research Future; 2023.